Evidence map›Paper›PMID 30086237›Full record

ArticleACS chemical neuroscience2019

Discovery of Tricyclic Triazolo- and Imidazopyridine Lactams as M

Julie L Engers, Aaron M Bender, Jacob J Kalbfleisch, Hyekyung P Cho, Kaelyn S Lingenfelter, Vincent B Luscombe, Changho Han, Bruce J Melancon, Anna L Blobaum, Jonathan W Dickerson and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Julie L EngersVanderbilt Center for Neuroscience Drug Discovery , Vanderbilt University Medical Center , Nashville , Tennessee 37232 , United States.
Aaron M BenderVanderbilt Center for Neuroscience Drug Discovery , Vanderbilt University Medical Center , Nashville , Tennessee 37232 , United States.
Jacob J KalbfleischVanderbilt Center for Neuroscience Drug Discovery , Vanderbilt University Medical Center , Nashville , Tennessee 37232 , United States.
Hyekyung P ChoVanderbilt Center for Neuroscience Drug Discovery , Vanderbilt University Medical Center , Nashville , Tennessee 37232 , United States.
Kaelyn S LingenfelterVanderbilt Center for Neuroscience Drug Discovery , Vanderbilt University Medical Center , Nashville , Tennessee 37232 , United States.
Vincent B LuscombeVanderbilt Center for Neuroscience Drug Discovery , Vanderbilt University Medical Center , Nashville , Tennessee 37232 , United States.
Changho HanVanderbilt Center for Neuroscience Drug Discovery , Vanderbilt University Medical Center , Nashville , Tennessee 37232 , United States.
Bruce J MelanconVanderbilt Center for Neuroscience Drug Discovery , Vanderbilt University Medical Center , Nashville , Tennessee 37232 , United States.
Anna L BlobaumVanderbilt Center for Neuroscience Drug Discovery , Vanderbilt University Medical Center , Nashville , Tennessee 37232 , United States.
Jonathan W DickersonVanderbilt Center for Neuroscience Drug Discovery , Vanderbilt University Medical Center , Nashville , Tennessee 37232 , United States.
Jerri M RookVanderbilt Center for Neuroscience Drug Discovery , Vanderbilt University Medical Center , Nashville , Tennessee 37232 , United States.
Colleen M NiswenderVanderbilt Center for Neuroscience Drug Discovery , Vanderbilt University Medical Center , Nashville , Tennessee 37232 , United States.
Kyle A EmmitteVanderbilt Center for Neuroscience Drug Discovery , Vanderbilt University Medical Center , Nashville , Tennessee 37232 , United States.ORCID 0000-0002-6643-3947
P Jeffrey ConnVanderbilt Center for Neuroscience Drug Discovery , Vanderbilt University Medical Center , Nashville , Tennessee 37232 , United States.
Craig W LindsleyVanderbilt Center for Neuroscience Drug Discovery , Vanderbilt University Medical Center , Nashville , Tennessee 37232 , United States.ORCID 0000-0003-0168-1445
Vanderbilt University · USVanderbilt University Medical Center · USUniversity of Notre Dame · US

Funding

Research Project: Sensory and Multisensory Contributions to AutismU54HD083211 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DYKENS, ELISABETH MAY · 2015 to 2019
$7.1M
Safety and tolerability testing of VU0467319: an M1 PAM for clinical developmentU19MH106839 · NIMH · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 2015 to 2017
$5.3M
Selective M1 mAChR allosteric modulators for the treatment of schizophreniaR01MH082867 · NIMH · VANDERBILT UNIVERSITY · PI LINDSLEY, CRAIG · 2008 to 2017
$3.7M
mGlu Allosteric Modulation in Neurodegenerative DiseasesR01AG051626 · NIA · VANDERBILT UNIVERSITY · PI ROOK, JERRI MICHELLE · 2016 to 2020
$2.0M
NIA NIH HHS R01 AG051626NICHD NIH HHS U54 HD083211NIMH NIH HHS R01 MH082867NIMH NIH HHS U19 MH106839
6 · The paper itself

Abstract

This Letter describes the chemical optimization of a new series of muscarinic acetylcholine receptor subtype 1 (M

Indexed as

Allosteric RegulationAnimalsDrug DiscoveryHumansImidazolesLactamsMiceMuscarinic AgonistsPyridinesRatsReceptor, Muscarinic M1ImidazolesimidazopyridineLactamsMuscarinic AgonistsPyridinesReceptor, Muscarinic M1CNSM1muscarinic acetylcholine receptor 1PAMPositive allosteric modulatorSAR

Identifiers

PMID30086237
PMCPMC6456254
OpenAlexW2886759412

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.